NASDAQ:HCWB HCW Biologics Q4 2024 Earnings Results & Report $1.17 -0.09 (-7.14%) Closing price 04:00 PM EasternExtended Trading$1.16 -0.01 (-0.85%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. HCW Biologics reported Q4 2024 earnings on March 28, 2025. The company reported EPS of -$19.20, while revenue was $0.40 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 28, 2025TimeDuring Market HoursConference Call8:00 AM ET HCW Biologics EPS ResultsActual EPS-$19.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate1 of last 5 quartersHCW Biologics Revenue ResultsActual Revenue$0.40 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsHCW Biologics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) HCW Biologics Q4 2024 Earnings FAQ Did HCW Biologics beat earnings estimates for Q4 2024? HCW Biologics (NASDAQ:HCWB) reported earnings of -$19.20 per share for Q4 2024. The report was announced on Friday, March 28, 2025. What was HCW Biologics' revenue for Q4 2024? HCW Biologics reported revenue of $0.40 million for Q4 2024. When is HCW Biologics' next earnings date? HCW Biologics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for HCW Biologics on the company's earnings history page. HCW Biologics Earnings HeadlinesHCW Biologics (NASDAQ:HCWB) Stock Rating Lowered by Wall Street ZenOctober 10, 2026 | americanbankingnews.comHCW Biologics Reports FDA Type B Meeting Guidance for HCW11-018b IND Preparation in Solid TumorsOctober 9, 2026 | quiverquant.comQWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid TumorsOctober 9, 2026 | globenewswire.comHCW Biologics Prices $1.5M Private PlacementSeptember 24, 2026 | rttnews.comHCW Biologics Announces Strategic $1.5 Million FinancingSeptember 24, 2026 | tipranks.comSee More HCW Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email. Email Address About HCW BiologicsHCW Biologics (NASDAQ:HCWB) (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases. HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic. Its lead candidate, HCW9218, is an investigational fusion protein intended to stimulate immune responses while inhibiting transforming growth factor beta, a signaling protein involved in immune suppression and disease progression. The company has evaluated HCW9218 in clinical research involving cancer and other inflammation-related conditions. Founded in 2018, HCW Biologics is headquartered in the United States and has focused its development activities on advancing biologic therapies through clinical testing. The company’s programs are intended for potential applications in oncology, immune disorders and diseases associated with chronic inflammation, although its candidates remain investigational and have not been established as approved treatments.View HCW Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
